.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,977,268

« Back to Dashboard

Details for Patent: 6,977,268

Title: Methods and compositions for inhibition of angiogenesis with EM-138
Abstract:The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Inventor(s): D'Amato; Robert (Lancaster, PA)
Assignee: Children's Medical Center Corporation (Boston, MA)
Filing Date:Dec 19, 2001
Application Number:10/026,037
Claims:1. A method of treating a neovascular eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal a pharmaceutically effective amount of EM-138, ##STR19##

or an epoxide thereof or a hydrolysis product of an epoxide thereof.

2. The method of claim 1, wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

3. The method of claim 2, wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.

4. The method of claim 3, wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.

5. The method of claim 1, wherein the compound is administered in the form of a tablet or capsule.

6. The method of claim 1, wherein the compound is administered in the form of a lozenge, a capsule, a cachet, a tablet, a solution, a suspension, an emulsion, a bolus, a powder, a granule, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tampon or a pessary.

7. The method of claim 1, wherein the administration is oral, parenteral, transdermal or topical.

8. The method of claim 1, wherein the administration is bulingual, buccal, rectal, vaginal or nasal.

9. The method of claim 1, wherein the eye condition is diabetic retinopathy.

10. The method of claim 1, wherein the eye condition is retinopathy of prematurity.

11. The method of claim 1, wherein the eye condition is corneal graft rejection.

12. The method of claim 1, wherein the eye condition is neovascular glaucoma.

13. The method of claim 1, wherein the eye condition is retrolental fibroplasias.

14. The method of claim 1, wherein the eye condition is epidemic keratoconjunctivitis.

15. The method of claim 1, wherein the eye condition is Vitamin A deficiency.

16. The method of claim 1, wherein the eye condition is contact lens overwear.

17. The method of claim 1, wherein the eye condition is atopic keratitis.

18. The method of claim 1, wherein eye condition is superior limbic keratitis.

19. The method of claim 1, wherein the eye condition is pterygium keratitis sicca.

20. The method of claim 1, wherein the eye condition is myopia.

21. The method of claim 1, wherein the eye condition is Terrien's marginal degeneration.

22. The method of claim 1, wherein the eye condition is marginal keratolysis.

23. The method of claim 1, wherein the eye condition is radial keratotomy.

24. The method of claim 1, wherein the eye condition is macular degeneration.

25. The method of claim 1, wherein the eye condition is post-laser complications.

26. The method of claim 1, wherein the eye condition is chronic retinal detachment.

27. The method of claim 1, wherein the eye condition is optic pits.

28. The method of claim 1, wherein the eye condition is hyperviscosity syndrome.

29. The method of claim 1, wherein the eye condition is chronic uveitis.

30. The method of claim 1, wherein the eye condition is chronic vitritis.

31. The method of claim 1, wherein the eye condition is age-related macular degeneration.

32. The method of claim 1, wherein the eye condition is presumed ocular histoplasmosis.

33. The method of claim 1, wherein the eye condition is an infection causing retinitis or choroiditis.

34. The method of claim 1, wherein the eye condition is proliferative vitreoretinopathy.

35. The method of claim 1, wherein the eye condition is scleritis.

36. The method of claim 1, wherein the eye condition is Eales' disease.

37. The method of claim 1, wherein the eye condition is Best's disease.

38. The method of claim 1, wherein the eye condition is trachoma.

39. The method of claim 1, further comprising an additive selected from an anti-oxidant, a buffer, a bacteriostat, a solute which renders the composition isotonic with the blood of the human or the animal, a suspending agent, a thicking agent, a flavoring agent, a gelatin, glycerine, a diluent, or any combination thereof.

40. The composition of claim 1, further comprising a biodegradable polymer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc